EQ
Equillium, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.21
−0.45%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +6.8%
- EBIT
- +5.7%
- EPS
- +54.2%
- Free cash flow
- +9.3%
- Operating cash flow
- +9.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +8.5%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -69.6%
- Free cash flow
- -19.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026